{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T18:08:28Z","timestamp":1765994908843,"version":"build-2065373602"},"reference-count":52,"publisher":"MDPI AG","issue":"20","license":[{"start":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T00:00:00Z","timestamp":1633910400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI15\/00711 and PI18\/00573"],"award-info":[{"award-number":["PI15\/00711 and PI18\/00573"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","award":["PI15\/00711 and PI18\/00573"],"award-info":[{"award-number":["PI15\/00711 and PI18\/00573"]}],"id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014139","name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de C\u00e1ncer","doi-asserted-by":"publisher","award":["CB16\/12\/00231)"],"award-info":[{"award-number":["CB16\/12\/00231)"]}],"id":[{"id":"10.13039\/501100014139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002704","name":"Fundaci\u00f3n Cient\u00edfica Asociaci\u00f3n Espa\u00f1ola Contra el C\u00e1ncer","doi-asserted-by":"publisher","award":["POSTD004MACI - POSTD16 and Predoctoral fellowship to IR"],"award-info":[{"award-number":["POSTD004MACI - POSTD16 and Predoctoral fellowship to IR"]}],"id":[{"id":"10.13039\/501100002704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009410","name":"Universitat de Lleida","doi-asserted-by":"publisher","award":["Predoctoral grant to PS"],"award-info":[{"award-number":["Predoctoral grant to PS"]}],"id":[{"id":"10.13039\/501100009410","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014540","name":"Xarxa de Bancs de Tumors de Catalunya","doi-asserted-by":"publisher","award":["B.0000682"],"award-info":[{"award-number":["B.0000682"]}],"id":[{"id":"10.13039\/501100014540","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Plataforma de Biobancos","award":["PT17\/0015\/0027; PT20\/00021"],"award-info":[{"award-number":["PT17\/0015\/0027; PT20\/00021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Cutaneous melanoma shows high variability regarding clinicopathological presentation, evolution and prognosis. Methods: Next generation sequencing was performed to analyze hotspot mutations in different areas of primary melanomas (MMp) and their paired metastases. Clinicopathological features were evaluated depending on the degree of variation of the BRAFV600E mutant allele frequency (MAF) in MMp. Results: In our cohort of 14 superficial spreading, 10 nodular melanomas and 52 metastases, 17\/24 (71%) melanomas had a BRAFV600E mutation and 5\/24 (21%) had a NRASQ61 mutation. We observed a high variation of BRAFV600E MAF (H-BRAFV600E) in 7\/17 (41%) MMp. The H-BRAFV600E MMp were all located on the trunk, had lower Breslow and mitotic indexes and predominantly, a first nodal metastasis. Regions with spindled tumor cells (Spin) and high lymphocytic infiltrate (HInf) were more frequent in the H-BRAFV600E patients (4\/7; 57%), whereas regions with epithelial tumor cells (Epit) and low lymphocytic infiltrate (LInf) were predominant (6\/10; 60%) and exclusive in the low BRAFV600E MAF variation tumors (L-BRAFV600E). The H-BRAFV600E\/Spin\/HInf MMp patients had better prognostic features and nodal first metastasis. Conclusions: The H-BRAFV600E MMp were located on the trunk, had better prognostic characteristics, such as lower Breslow and mitotic indexes as well as high lymphocytic infiltrate.<\/jats:p>","DOI":"10.3390\/cancers13205073","type":"journal-article","created":{"date-parts":[[2021,10,11]],"date-time":"2021-10-11T09:16:42Z","timestamp":1633943802000},"page":"5073","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["BRAFV600E Mutant Allele Frequency (MAF) Influences Melanoma Clinicopathologic Characteristics"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5644-1214","authenticated-orcid":false,"given":"Xavier","family":"Soria","sequence":"first","affiliation":[{"name":"Department of Dermatology, Hospital Universitari Arnau de Vilanova de Lleida, Institut de Recerca Biom\u00e8dica de Lleida (IRBLleida), Universitat de Lleida, 25198 Lleida, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felip","family":"Vilardell","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova de Lleida, Institut de Recerca Biom\u00e8dica de Lleida (IRBLleida), Universitat de Lleida, 25198 Lleida, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d3scar","family":"Maiques","sequence":"additional","affiliation":[{"name":"Tumour Microenvironment, Barts Cancer Institute, Queen Mary University of London, London EC1M 6BQ, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Barcel\u00f3","sequence":"additional","affiliation":[{"name":"Oncological Pathology Group, Institut de Recerca Biom\u00e8dica de Lleida (IRBLleida), 25198 Lleida, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pol","family":"Sis\u00f3","sequence":"additional","affiliation":[{"name":"Oncological Pathology Group, Institut de Recerca Biom\u00e8dica de Lleida (IRBLleida), 25198 Lleida, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"In\u00e9s","family":"de la Rosa","sequence":"additional","affiliation":[{"name":"Oncological Pathology Group, Institut de Recerca Biom\u00e8dica de Lleida (IRBLleida), 25198 Lleida, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Velasco","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova de Lleida, Institut de Recerca Biom\u00e8dica de Lleida (IRBLleida), Universitat de Lleida, 25198 Lleida, Spain"},{"name":"Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dolors","family":"Cuevas","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova de Lleida, Institut de Recerca Biom\u00e8dica de Lleida (IRBLleida), Universitat de Lleida, 25198 Lleida, Spain"},{"name":"Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Santacana","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova de Lleida, Institut de Recerca Biom\u00e8dica de Lleida (IRBLleida), Universitat de Lleida, 25198 Lleida, Spain"},{"name":"Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S\u00f2nia","family":"Gatius","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova de Lleida, Institut de Recerca Biom\u00e8dica de Lleida (IRBLleida), Universitat de Lleida, 25198 Lleida, Spain"},{"name":"Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Mat\u00edas-Guiu","sequence":"additional","affiliation":[{"name":"Department of Pathology and Molecular Genetics, Hospital Universitari Arnau de Vilanova de Lleida, Institut de Recerca Biom\u00e8dica de Lleida (IRBLleida), Universitat de Lleida, 25198 Lleida, Spain"},{"name":"Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Rodrigo","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Hospital Universitari Arnau de Vilanova de Lleida, Institut de Recerca Biom\u00e8dica de Lleida (IRBLleida), Universitat de Lleida, 25198 Lleida, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6038-178X","authenticated-orcid":false,"given":"Anna","family":"Maci\u00e0","sequence":"additional","affiliation":[{"name":"Unitat de Farmacologia- Department of Experimental Medicine, Universitat de Lleida, 25198 Lleida, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6866-6114","authenticated-orcid":false,"given":"Rosa M.","family":"Mart\u00ed","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Hospital Universitari Arnau de Vilanova de Lleida, Institut de Recerca Biom\u00e8dica de Lleida (IRBLleida), Universitat de Lleida, 25198 Lleida, Spain"},{"name":"Centre of Biomedical Research on Cancer (CIBERONC), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,10,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3322\/caac.21409","article-title":"Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual","volume":"67","author":"Gershenwald","year":"2017","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/nrc3218","article-title":"From Genes to Drugs: Targeted Strategies for Melanoma","volume":"12","author":"Flaherty","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF Gene in Human Cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/j.cell.2015.05.044","article-title":"Genomic Classification of Cutaneous Melanoma","volume":"161","author":"Akbani","year":"2015","journal-title":"Cell"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3242","DOI":"10.1158\/1078-0432.CCR-12-0052","article-title":"Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF -Mutant Metastatic Melanoma","volume":"18","author":"Menzies","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1038\/jid.2014.366","article-title":"Beyond BRAF V600: Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma","volume":"135","author":"Siroy","year":"2015","journal-title":"J. Investig. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1007\/s10552-014-0443-x","article-title":"Association between BRAF V600E and NRAS Q61R Mutations and Clinicopathologic Characteristics, Risk Factors and Clinical Outcome of Primary Invasive Cutaneous Melanoma","volume":"25","author":"Wu","year":"2014","journal-title":"Cancer Causes Control"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"500","DOI":"10.5858\/arpa.2019-0561-RA","article-title":"The 2018 World Health Organization Classification of Cutaneous, Mucosal, and Uveal Melanoma: Detailed Analysis of 9 Distinct Subtypes Defined by Their Evolutionary Pathway","volume":"144","author":"Elder","year":"2020","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/PAI.0000000000000071","article-title":"BRAF and NRAS Mutations Are Heterogeneous and Not Mutually Exclusive in Nodular Melanoma","volume":"23","author":"Chiappetta","year":"2015","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.18632\/oncotarget.1892","article-title":"Pathways and Therapeutic Targets in Melanoma","volume":"5","author":"Shtivelman","year":"2014","journal-title":"Oncotarget"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Savoia, P., Fava, P., Casoni, F., and Cremona, O. (2019). Targeting the ERK Signaling Pathway in Melanoma. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061483"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3109\/10799893.2015.1030412","article-title":"Signaling Pathway of MAPK\/ERK in Cell Proliferation, Differentiation, Migration, Senescence and Apoptosis","volume":"35","author":"Sun","year":"2015","journal-title":"J. Recept. Signal Transduct. Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1097\/CCO.0000000000000614","article-title":"Targeting BRAF and MEK Inhibitors in Melanoma in the Metastatic, Neoadjuvant and Adjuvant Setting","volume":"32","author":"Baroudjian","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Czarnecka, A.M., Bartnik, E., Fiedorowicz, M., and Rutkowski, P. (2020). Targeted Therapy in Melanoma and Mechanisms of Resistance. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21134576"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Sevilla, A., Morales, M.C., Ezkurra, P.A., Rasero, J., Velasco, V., Cancho-Galan, G., S\u00e1nchez-Diez, A., Mujika, K., Penas, C., and Smith, I. (2020). BRAF V600E Mutational Load as a Prognosis Biomarker in Malignant Melanoma. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0230136"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/00000658-197011000-00017","article-title":"Thickness, Cross-Sectional Areas and Depth of Invasion in the Prognosis of Cutaneous Melanoma","volume":"172","author":"Breslow","year":"1970","journal-title":"Ann. Surg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1200\/JCO.2006.08.1463","article-title":"Identification of High-Risk Patients Among Those Diagnosed With Thin Cutaneous Melanomas","volume":"25","author":"Gimotty","year":"2007","journal-title":"JCO"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/00000658-197812000-00004","article-title":"A Multifactorial Analysis of Melanoma: Prognostic histopathological features comparing Clark\u2019s and Breslow\u2019s staging methods","volume":"188","author":"Balch","year":"1978","journal-title":"Ann. Surg."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1200\/JCO.2011.38.8561","article-title":"Population-Based 20-Year Survival Among People Diagnosed With Thin Melanomas in Queensland, Australia","volume":"30","author":"Green","year":"2012","journal-title":"JCO"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1007\/s12094-019-02064-4","article-title":"Mitotic Rate as an Important Prognostic Factor in Cutaneous Malignant Melanoma","volume":"21","year":"2019","journal-title":"Clin. Transl. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jaad.2016.08.066","article-title":"Mitotic Rate Correlates with Sentinel Lymph Node Status and Outcome in Cutaneous Melanoma Greater than 1 Millimeter in Thickness: A Multi-Institutional Study of 1524 Cases","volume":"76","author":"Galli","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.surg.2018.04.016","article-title":"Tumor Mitotic Rate Is an Independent Predictor of Survival for Nonmetastatic Melanoma","volume":"164","author":"Evans","year":"2018","journal-title":"Surgery"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"37895","DOI":"10.18632\/oncotarget.5634","article-title":"Allele Frequencies of BRAF V600 Mutations in Primary Melanomas and Matched Metastases and Their Relevance for BRAF Inhibitor Therapy in Metastatic Melanoma","volume":"6","author":"Satzger","year":"2015","journal-title":"Oncotarget"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/CMR.0000000000000088","article-title":"BRAF V600 Mutation Levels Predict Response to Vemurafenib in Metastatic Melanoma","volume":"24","author":"Battistella","year":"2014","journal-title":"Melanoma Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1158\/1535-7163.MCT-17-1124","article-title":"BRAF Gene Copy Number and Mutant Allele Frequency Correlate with Time to Progression in Metastatic Melanoma Patients Treated with MAPK Inhibitors","volume":"17","author":"Stagni","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"100133","DOI":"10.1016\/j.esmoop.2021.100133","article-title":"High BRAF Variant Allele Frequencies Are Associated with Distinct Pathological Features and Responsiveness to Target Therapy in Melanoma Patients","volume":"6","author":"Berrino","year":"2021","journal-title":"ESMO Open"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"7355","DOI":"10.2147\/OTT.S99807","article-title":"Next-Generation Sequencing: Advances and Applications in Cancer Diagnosis","volume":"9","author":"Pilato","year":"2016","journal-title":"OTT"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1002\/cpmb.59","article-title":"Overview of Next-Generation Sequencing Technologies","volume":"122","author":"Slatko","year":"2018","journal-title":"Curr. Protoc. Mol. Biol."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Mejbel, H.A., Arudra, S.K.C., Pradhan, D., Torres-Cabala, C.A., Nagarajan, P., Tetzlaff, M.T., Curry, J.L., Ivan, D., Duose, D.Y., and Luthra, R. (2019). Immunohistochemical and Molecular Features of Melanomas Exhibiting Intratumor and Intertumor Histomorphologic Heterogeneity. Cancers, 11.","DOI":"10.3390\/cancers11111714"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/bjd.15121","article-title":"Immunohistochemical Analysis of T-Type Calcium Channels in Acquired Melanocytic Naevi and Melanoma","volume":"176","author":"Maiques","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open Source Software for Digital Pathology Image Analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.tranon.2017.09.007","article-title":"Intratumor and Intertumor Heterogeneity in Melanoma","volume":"10","author":"Grzywa","year":"2017","journal-title":"Transl. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1001\/jamadermatol.2014.3689","article-title":"BRAF V600E Protein Expression in Primary Cutaneous Malignant Melanomas and Paired Metastases","volume":"151","author":"Eriksson","year":"2015","journal-title":"JAMA Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1097\/MD.0000000000000285","article-title":"BRAFV600E Immunopositive Melanomas Show Low Frequency of Heterogeneity and Association With Epithelioid Tumor Cells: A STROBE-Compliant Article","volume":"93","author":"Verlinden","year":"2014","journal-title":"Medicine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1016\/j.humpath.2015.04.012","article-title":"Utility of BRAF V600E Immunohistochemistry Expression Pattern as a Surrogate of BRAF Mutation Status in 154 Patients with Advanced Melanoma","volume":"46","author":"Tetzlaff","year":"2015","journal-title":"Hum. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1158\/1078-0432.CCR-15-1811","article-title":"Identification of a Novel Pathogenic Germline KDR Variant in Melanoma","volume":"22","author":"Silva","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_38","first-page":"6483","article-title":"NRAS and BRAF Mutations Arise Early during Melanoma Pathogenesis and Are Preserved throughout Tumor Progression","volume":"9","author":"Omholt","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1097\/01.cmr.0000232300.22032.86","article-title":"NRAS and BRAF Mutations in Melanoma Tumours in Relation to Clinical Characteristics: A Study Based on Mutation Screening by Pyrosequencing","volume":"16","author":"Egyha","year":"2006","journal-title":"Melanoma Res."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.jaad.2015.02.1113","article-title":"Metaanalysis of BRAF Mutations and Clinicopathologic Characteristics in Primary Melanoma","volume":"72","author":"Kim","year":"2015","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"100750","DOI":"10.1016\/j.tranon.2020.100750","article-title":"Frequency and Clinicopathological Profile Associated with Braf Mutations in Patients with Advanced Melanoma in Spain","volume":"13","year":"2020","journal-title":"Transl. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2133.2010.10185.x","article-title":"Frequencies of BRAF and NRAS Mutations Are Different in Histological Types and Sites of Origin of Cutaneous Melanoma: A Meta-Analysis: BRAF and NRAS Mutations in Melanoma","volume":"164","author":"Lee","year":"2011","journal-title":"Br. J. Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4499","DOI":"10.1158\/1078-0432.CCR-05-2447","article-title":"Cutaneous Melanoma Subtypes Show Different BRAF and NRAS Mutation Frequencies","volume":"12","author":"Saldanha","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/CMR.0000000000000628","article-title":"Frequency of Mutations in BRAF, NRAS, and KIT in Different Populations and Histological Subtypes of Melanoma: A Systemic Review","volume":"30","author":"Nova","year":"2020","journal-title":"Melanoma Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s00428-018-2393-2","article-title":"Comparison of Targeted next Generation Sequencing (NGS) versus Isolated BRAF V600E Analysis in Patients with Metastatic Melanoma","volume":"473","author":"Zhu","year":"2018","journal-title":"Virchows Arch."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1097\/PAS.0000000000000136","article-title":"Intrapatient Homogeneity of BRAFV600E Expression in Melanoma","volume":"38","author":"Menzies","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1097\/DSS.0000000000001643","article-title":"Satellite and In-Transit Metastatic Disease in Melanoma Skin Cancer: A Retrospective Review of Disease Presentation, Treatment, and Outcomes","volume":"45","author":"Bann","year":"2019","journal-title":"Dermatol. Surg."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejso.2016.10.005","article-title":"Diagnosis and Treatment of In-Transit Melanoma Metastases","volume":"43","author":"Testori","year":"2017","journal-title":"Eur. J. Surg. Oncol. (EJSO)"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1200\/JCO.2011.37.8539","article-title":"Tumor-Infiltrating Lymphocyte Grade Is an Independent Predictor of Sentinel Lymph Node Status and Survival in Patients With Cutaneous Melanoma","volume":"30","author":"Azimi","year":"2012","journal-title":"JCO"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1200\/JCO.2013.51.3002","article-title":"Tumor-Infiltrating Lymphocyte Grade in Primary Melanomas Is Independently Associated With Melanoma-Specific Survival in the Population-Based Genes, Environment and Melanoma Study","volume":"31","author":"Thomas","year":"2013","journal-title":"JCO"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e1593806","DOI":"10.1080\/2162402X.2019.1593806","article-title":"Prognostic Value of Tumor-Infiltrating Lymphocytes in Melanoma: A Systematic Review and Meta-Analysis","volume":"8","author":"Fu","year":"2019","journal-title":"OncoImmunology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5315","DOI":"10.1038\/s41467-020-18951-2","article-title":"WNT11-FZD7-DAAM1 Signalling Supports Tumour Initiating Abilities and Melanoma Amoeboid Invasion","volume":"11","author":"Maiques","year":"2020","journal-title":"Nat. Commun."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/20\/5073\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:11:28Z","timestamp":1760166688000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/20\/5073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,11]]},"references-count":52,"journal-issue":{"issue":"20","published-online":{"date-parts":[[2021,10]]}},"alternative-id":["cancers13205073"],"URL":"https:\/\/doi.org\/10.3390\/cancers13205073","relation":{},"ISSN":["2072-6694"],"issn-type":[{"type":"electronic","value":"2072-6694"}],"subject":[],"published":{"date-parts":[[2021,10,11]]}}}